Tag: drug-coated balloons
Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF
Concept Medical has provided an update on the progress of the IMPRESSION (Sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease received treatment with paclitaxel-coated (drug-coated balloons or...
Paclitaxel situation “crystallising” thanks to new data and teamwork, VIVA audience...
This year's Vascular Interventional Advances annual meeting (VIVA 2020; 6–8 November, online) opened with a session on controversial hot topics and advanced multidisciplinary approaches...
Paclitaxel mortality signal inconsistent across different geographies
While drug-coated balloons (DCBs) have been “consistently efficacious” across various studies, the mortality signal has not, Peter Schneider (University of California San Francisco, San...
Analysis of DCB use for treatment of central venous stenosis shows...
According to the findings of a European multicentre retrospective analysis, the use of drug-coated balloons (DCBs) for the treatment of symptomatic central venous stenosis...
VIVA 2019: SELUTION sirolimus DCB safe and effective through two years
The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...
Philips receives FDA approval for low-dose drug-coated balloons
Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of...
A panel of experts comments on IN.PACT AV ACCESS data
NOTE: This video is ONLY available to watch in selected countries and geographies
Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...
MHRA issues medical device alert for paclitaxel use in the UK
Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
Meta-analysis finds a higher risk of death in the long term...
New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
Without additional long-term and patient-level data, Katsanos et al’s conclusion is...
By Thomas Zeller
The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...
Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB
After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...
Particulate embolisation after femoral artery treatment with drug-coated balloons
Drug-eluting technologies, such as balloons coated with paclitaxel (DCB), are now the gold standard treatment for patients presenting with symptomatic peripheral artery disease (PAD) in the...
Global cohorts report drug-coated balloon success above the knee and “promising”...
Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...
Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon
Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...
Initial patients enrolled in first-in-man study of Selution sirolimus-coated balloon
Med Alliance has announced first patient enrolment in the first-in-man study of the Selution novel sirolimus-coated balloon. Patients were enrolled at the Universitaets-Herzzentrum, Bad...
